Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252239 · ClinicalTrials.gov registry record · Phase 2
Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)
A Phase 2 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT00252239 is a Phase 2 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 112 participants.
The verdict
NCT00252239, a Phase 2 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to determine which of 3 different doses of tenecteplase (TNK) is better for treating stroke patients and if TNK offers an advantage over currently available treatment with tissue plasminogen activator (tPA).
Interventions
- DRUG tenecteplase
- DRUG tissue plasminogen activator, tPA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2005-11 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252239
The ClinicalTrials.gov registry entry for NCT00252239 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tenecteplase is the first listed.
NCT00252239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00252239 about?
NCT00252239 is a clinical study titled "Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)". The purpose of this study is to determine which of 3 different doses of tenecteplase (TNK) is better for treating stroke patients and if TNK offers an advantage over currently available treatment with tissue plasminogen activator (tPA).
What is the current status of trial NCT00252239?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2005-11. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00252239?
The interventions under investigation include: tenecteplase (DRUG), tissue plasminogen activator, tPA (DRUG).
Who is sponsoring clinical trial NCT00252239?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.